Acumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on Tuesday

Key Points

• Acumen Pharmaceuticals is set to announce its Q2 2025 earnings on August 12, 2025, with analysts predicting a loss of ($0.54) per share.
• The company reported a smaller-than-expected loss of ($0.48) EPS last quarter, exceeding analysts’ estimates of ($0.56) by $0.08.
• Citigroup has initiated coverage on Acumen Pharmaceuticals with a "buy" rating and a price target of $4.00 per share.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.54) per share for the quarter.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. During the same period last year, the company earned ($0.25) EPS. On average, analysts expect Acumen Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acumen Pharmaceuticals Trading Down 4.2%

ABOS traded down $0.06 during midday trading on Friday, hitting $1.36. 140,856 shares of the company were exchanged, compared to its average volume of 580,706. The firm has a market capitalization of $82.38 million, a P/E ratio of -0.70 and a beta of 0.14. Acumen Pharmaceuticals has a 1-year low of $0.86 and a 1-year high of $3.36. The firm's 50 day moving average price is $1.29 and its 200-day moving average price is $1.23. The company has a quick ratio of 8.02, a current ratio of 8.02 and a debt-to-equity ratio of 0.19.

Analyst Upgrades and Downgrades

Separately, Citigroup initiated coverage on Acumen Pharmaceuticals in a research report on Tuesday, June 17th. They issued a "buy" rating and a $4.00 target price for the company.

Institutional Investors Weigh In On Acumen Pharmaceuticals

An institutional investor recently bought a new position in Acumen Pharmaceuticals stock. AQR Capital Management LLC bought a new position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 41,735 shares of the company's stock, valued at approximately $46,000. AQR Capital Management LLC owned about 0.07% of Acumen Pharmaceuticals at the end of the most recent reporting period. 71.01% of the stock is currently owned by hedge funds and other institutional investors.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.